Scholar Rock Holding Corp
2QK
Company Profile
Business description
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
Contact
301 Binney Street
3rd Floor
CambridgeMA02142
USAT: +1 857 259-3860
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
196
Stocks News & Analysis
stocks
Cutting our fair value on ASX share after poor guidance
Our view after the shares stand after a 20% drop.
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,858.90 | 42.40 | -0.48% |
| CAC 40 | 8,052.51 | 55.92 | -0.69% |
| DAX 40 | 24,162.65 | 116.64 | 0.49% |
| Dow JONES (US) | 47,560.29 | 179.03 | -0.38% |
| FTSE 100 | 9,642.01 | 3.08 | -0.03% |
| HKSE | 25,352.01 | 82.22 | -0.32% |
| NASDAQ | 23,576.49 | 30.58 | 0.13% |
| Nikkei 225 | 50,346.75 | 308.35 | -0.61% |
| NZX 50 Index | 13,398.80 | 87.52 | -0.65% |
| S&P 500 | 6,840.51 | 6.00 | -0.09% |
| S&P/ASX 200 | 8,572.20 | 38.90 | -0.45% |
| SSE Composite Index | 3,885.07 | 24.45 | -0.63% |